NeuroPace, Inc. (NPCE)

NeuroPace's stock has experienced several notable events in the past six months. The company reported record quarterly revenue of $27.4 million in Q3 2025, representing 30% growth compared to Q3 2024, and increased its full-year 2025 revenue guidance to between $97 million and $98 million. In December 2025, NeuroPace announced positive 18-month results from its NAUTILUS trial for idiopathic generalized epilepsy (IGE) and subsequently filed a Premarket Approval Supplement (PMA-S) application with the U.S. Food and Drug Administration (FDA) to expand the labeled indication for its RNS System to include patients with antiseizure-medication (ASM) resistant IGE with generalized tonic-clonic seizures. In January 2026, NeuroPace reported preliminary unaudited results for the fourth quarter and full year 2025, with total revenue of approximately $26.6 million for Q4 2025 (a 24% increase over Q4 2024) and approximately $100 million for the full year 2025 (a 25% increase over 2024). Additionally, in November 2025, NeuroPace announced favorable Medicare reimbursement increases for RNS System physician and hospital outpatient services. Short interest in NeuroPace has recently increased by 3.17%, indicating a decrease in investor sentiment. As of February 5, 2026, the stock price was $15.49.

There is no explicit information available indicating significant demand seasonality for NeuroPace, Inc.'s products and services. The demand for its RNS System is primarily driven by the prevalence of drug-resistant epilepsy and the expansion of access to its therapy. The company's growth is linked to factors such as stronger implant rates, higher gross margins, regulatory label expansion for new indications, and the institutionalization of RNS into care pathways.

NeuroPace, Inc., a medical technology company in Mountain View, California, specializes in brain-responsive neuromodulation systems. Their flagship product, the RNS System, is an implantable device that monitors brain activity and delivers targeted electrical pulses to prevent seizures in adults with medically refractory focal epilepsy. The system includes the RNS neurostimulator, leads, a Patient Remote Monitor, and accessories. NeuroPace also provides a physician tablet, a patient data management system, and the nSight Platform for patient monitoring and support. The company sells its products primarily to hospital facilities for initial and replacement RNS System implant procedures.

NeuroPace, Inc. primarily operates in the United States, where its RNS System holds regulatory approvals. The company has also obtained CE Mark certification for the RNS System, allowing its use in select European countries.

NeuroPace maintains a "Moderate Buy" consensus rating from analysts, with an average rating score of 2.63. Analysts anticipate a potential upside of 19.1% from its current price. The company's MarketBeat news sentiment score is 0.58, which is lower than the average news sentiment score of 0.84 for medical companies. NeuroPace is recognized for its RNS System, which has demonstrated a significant improvement in the quality of life for patients with drug-resistant epilepsy. Recent positive events that have likely contributed to its reputation include the positive 18-month NAUTILUS trial results for IGE and the subsequent filing of a PMA supplement with the FDA for an expanded indication, as well as favorable Medicare reimbursement increases.

NeuroPace, Inc. has significant institutional ownership, with 78.83% of its stock held by institutions. Major institutional shareholders include Polar Capital Holdings Plc, Soleus Capital Management, L.P., Orbimed Advisors Llc, Morgan Stanley, BlackRock, Inc., Vanguard Group Inc, First Light Asset Management, LLC, Armistice Capital, Llc, Kent Lake PR LLC, and Driehaus Capital Management Llc. Insiders hold 20.50% of the company's stock, including Orbimed Advisors Llc, Martha Morrell, and Ltd Kck.